ROTABLATOR Rotational Atherectomy System
Boston Scientific Corp · Decision date Aug 14, 2025
What did the FDA approve?
FDA records P900056/S221 as a supplement to PMA P900056, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 14, 2025.
FDA approval order statement
for a manufacturing site located at Boston Scientific de Costa Rica, S.R.L., El Coyol Alajuela, Coyol, Costa Rica (FEI: 3007695959) to perform ethylene oxide sterilization activities
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 14, 2025
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P900056/S221
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- Decision code
- APPR
- Decision date
- Aug 14, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: CATHETER, CORONARY, ATHERECTOMY.
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.
FDA decision timeline
P900056 · Original PMA
ROTABLATOR(R)
P900056/S221 received
Application receipt date recorded by FDA.
P900056/S221 · FDA decision
Normal 180 Day Track No User Fee
P900056/S222 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S223 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S224 · Related supplement
Rotablator; ROTAPRO Rotational Atherectomy Systems
P900056/S225 · Related supplement
ROTABLATOR Rotational Atherectomy System
P900056/S228 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S226 · Related supplement
ROTAPRO Rotational Atherectomy Systems
P900056/S229 · Related supplement
ROTAPRO Rotational Atherectomy System
Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P900056
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ROTABLATOR(R)P900056 | Boston Scientific Corp | PMA approval | May 28, 1993 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S222 | Boston Scientific Corp | PMA supplement | Oct 27, 2025 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S223 | Boston Scientific Corp | PMA supplement | Mar 5, 2026 | FDA |
| Boston Scientific Corp | PMA supplement | Apr 9, 2026 | FDA | |
ROTABLATOR Rotational Atherectomy SystemP900056/S225 | Boston Scientific Corp | PMA supplement | May 6, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S228 | Boston Scientific Corp | PMA supplement | Oct 20, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemsP900056/S226 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S229 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
Explore the linked device profile
Other records with product code MCX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cardiovascular Systems, Inc. | PMA supplement | Mar 10, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Feb 26, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Feb 18, 2026 | FDA | |
| Cardiovascular Systems, Inc. | PMA supplement | Jan 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- Two Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P900056/S221
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





